Response to azacitidine in MPN having progressed to MDS and AML
| . | All (n = 54) . | WHO classification at progression . | |
|---|---|---|---|
| AML (n = 26) . | MDS (n = 28) . | ||
| Responses | |||
| CR, n ( % ) | 10 (19) | 2 (8) | 8 (29) |
| Cytogenetic CR, n (%) | 3 (6) | 1 (4) | 2 (7) |
| CRi, n (%) | 1 (2) | 1 (4) | † |
| Marrow CR, n (%) | 3 (6) | * | 3 (11) |
| PR, n (%) | 6 (11) | 6 (23) | |
| Stable with HI, n (%) | 5 (9) | * | 5 (21) |
| Stable without HI, n (%) | 3 (6) | * | 3 (11) |
| Progression, n (%) | 24 (44) | 16 (62) | 8 (29) |
| Overall response rate, n (%) | 28 (52) | ||
| CR + CRi + PR, n (%)† | 10 (38) | ||
| CR + marrow CR + PR + stable with HI, n (%)* | 18 (64) | ||
| . | All (n = 54) . | WHO classification at progression . | |
|---|---|---|---|
| AML (n = 26) . | MDS (n = 28) . | ||
| Responses | |||
| CR, n ( % ) | 10 (19) | 2 (8) | 8 (29) |
| Cytogenetic CR, n (%) | 3 (6) | 1 (4) | 2 (7) |
| CRi, n (%) | 1 (2) | 1 (4) | † |
| Marrow CR, n (%) | 3 (6) | * | 3 (11) |
| PR, n (%) | 6 (11) | 6 (23) | |
| Stable with HI, n (%) | 5 (9) | * | 5 (21) |
| Stable without HI, n (%) | 3 (6) | * | 3 (11) |
| Progression, n (%) | 24 (44) | 16 (62) | 8 (29) |
| Overall response rate, n (%) | 28 (52) | ||
| CR + CRi + PR, n (%)† | 10 (38) | ||
| CR + marrow CR + PR + stable with HI, n (%)* | 18 (64) | ||
MPN indicates myeloproliferative neoplasm; AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; WHO, World Health Organization; CR, complete response, CRi, complete response with incomplete recovery of cytopenias; PR, partial response; HI, hematologic improvement.
International Working Group 2006 response criteria for MDS.
International Working Group 2003 response criteria for AML.